EMERYVILLE, Calif., Nov. 11, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that it has entered into an Accelerated Share Repurchase transaction ("ASR") under an agreement with Goldman Sachs & Co. LLC to repurchase $100 million of the Company's common stock. Dynavax executed the ASR as part of the $200 million share repurchase program authorized by its Board of Directors in ...

Dynavax Technologies Corporation (NASDAQ:DVAX) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communications Ryan Spencer - Chief Executive Officer Donn Casale - Chief Commercial Officer Rob Janssen - Chief Medical Officer Kelly MacDonald - Chief Financial Officer Conference Call Participants Matt Phipps - William Blair Jon Miller - Evercore Ernie Rodriguez - TD Cowen Paul Choi - Goldman Sachs Roy Buchanan - Citizen ...

| --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | Q3 2024 Financial Results | | | | | | Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases | | | | | | | | | | | | November 2024 Nasdaq: DVAX | | | | | Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward-l ...

Dynavax Technologies (DVAX) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.06 per share when it actually produced earnings of $0.08, delivering a surprise of 33.33%.Over the last four qu ...

Table of Contents Title of each class: Trading symbol(s): Name of each exchange on which registered: Common Stock, $0.001 par value DVAX Nasdaq Global Select Market Preferred Share Purchase Rights N/A Nasdaq Global Select Market Large accelerated filer x Accelerated filer o Non-accelerated filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________ Form 10-Q __________________ ...

Exhibit 99.1 Dynavax Reports Third Quarter 2024 Financial Results and Provides Business Updates • HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-overyear growth • Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share • Expect positive net income in 2024, achieving full year profitability • Strengthened cash position to $764 million in Q3'24 • $200 million sha ...

HEPLISAV-B® quarterly net product revenue of $79.3 million, representing 27% year-over-year growth Hepatitis B adult vaccine market expected to expand to a peak of over $900 million by 2030, with HEPLISAV-B expected to achieve at least 60% estimated total market share Expect positive net income in 2024, achieving full year profitability Strengthened cash position to $764 million in Q3'24  $200 million share repurchase program announced as part of balanced capital allocation strategy Conference call today ...

EMERYVILLE, Calif., Nov. 7, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced its Board of Directors has authorized the repurchase of up to $200 million of the Company's common stock. The share repurchase program does not have an expiration date and Dynavax currently expects that purchases will be executed within a period of up to one year."Dynavax maintains a disciplined and ...

EMERYVILLE, Calif., Oct. 29, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that its Board of Directors has adopted a limited-duration stockholder rights plan, effective immediately (the "Rights Plan"). The Dynavax Board adopted the Rights Plan in response to the recent rapid accumulations of stock by Deep Track Capital, which recently disclosed in a Schedule 13D/A filing i ...

EMERYVILLE, Calif., Oct. 24, 2024 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report third quarter 2024 financial results on Thursday, November 7, 2024, after the U.S. financial markets close.Dynavax will host a conference call and live audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT.The live audio webcast may be accessed through the "Events & Presentations" pa ...